Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine the percentage of patients who would reach a cholesterol goal after atorvastatin treatment.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| High Risk | Experimental |
| |
| Low Risk | Experimental |
| |
| Medium Risk | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Atorvastatin | Drug | Atorvastatin calcium 10, 20, 40, or 80 mg tablets (dose dependent on individual risk factors and baseline LDL-C level) once daily for 4 weeks. After 4 weeks of treatment, subjects who did not achieve the LDL-C target goal were up-titrated to 20, 40, or 80 mg and subjects who achieved their LDL-target goal remained on the same dose for the following 4 weeks. |
| Measure | Description | Time Frame |
|---|---|---|
| Responder rate in patients who achieved low-density lipoprotein cholesterol (LDL-C) level | Week 8 |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of patients achieving LDL goal at 2 and 4 weeks | Weeks 2 and 4 | |
| Lipid changes at week 4 & 8 | Weeks 4 and 8 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pfizer Investigational Site | Belo Horizonte | Minas Gerais | Brazil | |||
| Pfizer Investigational Site |
Not provided
| Label | URL |
|---|---|
| To obtain contact information for a study center near you, click here. | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Atorvastatin | Drug | Atorvastatin calcium 10, 20, 40, or 80 mg tablets (dose dependent on individual risk factors and baseline LDL-C level) once daily for 4 weeks. After 4 weeks of treatment, subjects who did not achieve the LDL-C target goal were up-titrated to 20, 40, or 80 mg and subjects who achieved their LDL-target goal remained on the same dose for the following 4 weeks. |
|
| Atorvastatin | Drug | Atorvastatin calcium 10, 20, 40, or 80 mg tablets (dose dependent on individual risk factors and baseline LDL-C level) once daily for 4 weeks. After 4 weeks of treatment, subjects who did not achieve the LDL-C target goal were up-titrated to 20, 40, or 80 mg and subjects who achieved their LDL-target goal remained on the same dose for the following 4 weeks. |
|
| Curitiba |
| Paraná |
| 80540-010 |
| Brazil |
| Pfizer Investigational Site | Porto Alegre | Rio Grande do Sul | 90035-170 | Brazil |
| Pfizer Investigational Site | Porto Alegre | Rio Grande do Sul | 90610-000 | Brazil |
| Pfizer Investigational Site | São José | Santa Catarina | 88103-460 | Brazil |
| Pfizer Investigational Site | São Paulo | SP/Brazil | 04039-001 | Brazil |
| Pfizer Investigational Site | Campinas | São Paulo | 13012-000 | Brazil |
| Pfizer Investigational Site | Campinas | São Paulo | 13059-740 | Brazil |
| Pfizer Investigational Site | São José do Rio Preto | São Paulo | 15090-000 | Brazil |
| Pfizer Investigational Site | São Paulo | São Paulo | 01244-030 | Brazil |
| Pfizer Investigational Site | São Paulo | São Paulo | 04012-180 | Brazil |
| Pfizer Investigational Site | São Paulo | São Paulo | Brazil |
| Pfizer Investigational Site | Rio de Janeiro | 20550-030 | Brazil |
| Pfizer Investigational Site | Santiago | Santiago Metropolitan | Chile |
| Pfizer Investigational Site | Bogota | Cundinamarca | Colombia |
| Pfizer Investigational Site | Bogotá | Cundinamarca | Colombia |
| Pfizer Investigational Site | Barranquilla | Colombia |
| Pfizer Investigational Site | Bogotá, C/marca | Colombia |
| Pfizer Investigational Site | Cali, Valle | Colombia |
| Pfizer Investigational Site | Quito | Pichincha / Ecuador | Ecuador |
| Pfizer Investigational Site | Guatemala City | 01015 | Guatemala |
| Pfizer Investigational Site | Guadalajara | Jalisco | 44290 | Mexico |
| Pfizer Investigational Site | Zapopan | Jalisco | 45200 | Mexico |
| Pfizer Investigational Site | Monterrey | Nuevo León | 64060 | Mexico |
| Pfizer Investigational Site | Monterrey | Nuevo León | 64410 | Mexico |
| Pfizer Investigational Site | Chihuahua City | 31238 | Mexico |
| Pfizer Investigational Site | Durango | 34300 | Mexico |
| Pfizer Investigational Site | Panama City | Panama |
| Pfizer Investigational Site | Caracas | Dtto Federal | 1061 | Venezuela |
| Pfizer Investigational Site | Caracas | Dtto Federal | 1081 | Venezuela |
| Pfizer Investigational Site | Caracas | Edo. Miranda | 1061 | Venezuela |
| Pfizer Investigational Site | Dtto. Federal | Miranda | 1020 | Venezuela |
| Pfizer Investigational Site | Caracas | 1020 | Venezuela |
| ID | Term |
|---|---|
| D050171 | Dyslipidemias |
| ID | Term |
|---|---|
| D052439 | Lipid Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000069059 | Atorvastatin |
| ID | Term |
|---|---|
| D011758 | Pyrroles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D006538 | Heptanoic Acids |
| D005227 | Fatty Acids |
| D008055 | Lipids |
Not provided
Not provided